Short answer
Inhibrx Biosciences, Inc. (INBX) filed an 8-K current report with the SEC on November 17, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Updated clinical data for ozekibart, or INBRX-109, in relapsed or refractory Ewing sarcoma.
Inhibrx Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Updated clinical data for ozekibart, or INBRX-109, in relapsed or refractory Ewing sarcoma
- Phase 1/2 expansion study evaluates ozekibart combined with irinotecan and temozolomide
- Data presentation at the Connective Tissue Oncology Society 2026 Annual Meeting
- Investor focus: efficacy and safety results could influence ozekibart’s development prospects and valuation
Item EX-99.1 · Exhibit EX-99.1
- Updated Phase 1/2 Ewing sarcoma data: 62.7% ORR and 86.3% DCR among 51 response-evaluable patients
- Responses included 2 complete responses and 30 partial responses, with 18 patients achieving benefit exceeding 6 months
- Median PFS 6.0 months, exceeding historical irinotecan-temozolomide benchmarks of roughly 3 to 4 months
- 22 of 60 treated patients remained on active treatment, supporting continued clinical momentum
- FDA accepted ozekibart’s chondrosarcoma BLA for filing, creating a separate regulatory catalyst beyond Ewing sarcoma
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibrx Biosciences, Inc. 8-K filings
Get the next INBX 8-K as it lands
Follow INBX for push alerts, or ask the research agent what this filing means.